- Newscope Capital Corporation, who through its wholly-owned subsidiary, PharmaTher Inc., announced that its common shares have been approved for trading on the OTCQB® Venture Market effective today.
Newscope Capital Corporation (PHRM) (OTCQB: PHRRF) (the “Company”), who through its wholly-owned subsidiary, PharmaTher Inc., is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture Market (“OTCQB”) effective today.
The Company’s U.S. listing will trade under the symbol “PHRRF” while the Company’s primary Canadian listing will continue to trade on the Canadian Securities Exchange under “PHRM”.
We are focused on developing our clinical-stage product pipeline of novel uses and delivery of ketamine for U.S. FDA approval to treat mental health, neurological and pain disorders, and with our common shares listed on the OTCQB it will help us to broaden our awareness and shareholder base with institutional and retail investors in the U.S.”
Fabio Chianelli – CEO of the Newscope Capital Corporation
The Company has also applied to the Depository Trust Company (“DTC”) for DTC eligibility, which would greatly simplify the process of trading the Company’s common shares. The Company expects to receive DTC eligibility approval shortly.
About PharmaTher Inc.
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat mental health, neurological and pain disorders.
Learn more at: PharmaTher.com and follow us on Twitter, LinkedIn and Facebook.